Exceptional Response of Metastatic Chromophobe Renal Cell Carcinoma to Vascular Endothelial Growth Factor (VEGF) Inhibitors: Should Increased VEGF-C Expression Be Used to Guide Treatment?

Exceptional Response of Metastatic Chromophobe Renal Cell Carcinoma to Vascular Endothelial Growth Factor (VEGF) Inhibitors: Should Increased VEGF-C Expression Be Used to Guide Treatment?

There is sparse literature demonstrating effective treatments for metastatic chromophobe renal cell carcinoma (ChRCC). The tyrosine kinase inhibitor (TKI) sunitinib selectively inhibits the VEGF pathway and it is a standard care for metastatic clear cell renal cell carcinoma (ccRCC), although data s...

Full description

Bibliographic Details
Main Authors: Jacob W. Bruinius, Karl J. Dykema, Sabrina L. Noyes, Bin Tean Teh, Brian R. Lane
Format: Article
Language:English
Published: Wiley 2019-01-01
Series:Case Reports in Urology
Online Access:http://dx.doi.org/10.1155/2019/2479823

Internet

http://dx.doi.org/10.1155/2019/2479823

Similar Items